News | October 01, 2008

CardioNet Launches Enhanced Reporting Package for the Treatment of Atrial Fibrillation

October 2, 2008 - Wireless medical technology company CardioNet Inc. today released its new atrial fibrillation (AF) reporting package to enhance its current AF management program.

The CardioNet AF Management Program offers a comprehensive tool to the physician for the diagnosis, treatment and management of their AF patients. The program provides physicians with a flexible monitoring program to evaluate the clinical efficacy of catheter and surgical ablation procedures allowing improved management of these post surgical patients.

The company said reporting enhancements will strengthen CardioNet’s current proprietary correlated Heart Rate Trend Chart and AF Burden Graph by providing detailed atrial fibrillation statistics, including the duration of AF episodes, the percentage of time that a patient is in AF over a 24-hour period, and heart rate trends while the patient is in AF.

The company said the CardioNet System is widely utilized by physicians and is proven to be nearly three times superior at detecting clinically significant atrial fibrillation1, a condition which affects 2.2 million people in the U.S.

For more information: www.cardionet.com


Related Content

News

Sept. 8, 2026 — Abbot has announced that it has received U.S. Food and Drug Administration (FDA) approval for the ...

Home September 08, 2026
Home
News

Aug. 31, 2026 — At the European Society of Cardiology Congress in Munich, Abbott announced new late-breaking 12-month ...

Home September 02, 2026
Home
News

July 8, 2026 — Johnson & Johnson has announced that the U.S. Food and Drug Administration (FDA) approved the Dual Energy ...

Home July 08, 2026
Home
News

May 21, 2026 — Adagio Medical Holdings, a provider of catheter ablation technologies for treating cardiac arrhythmias ...

Home May 22, 2026
Home
News

April 26, 2026 — New results from the multicenter catheter ablation versus anti-arrhythmic drugs for Ventricular ...

Home April 29, 2026
Home
News

April 24, 2026 — Johnson & Johnson recently announced the initiation of the PERSIGMA randomized controlled trial (RCT) ...

Home April 27, 2026
Home
News

April 26, 2026 – New results from the pivotal multicenter trial FULCRUM-VT show that ultra-low temperature ablation ...

Home April 27, 2026
Home
News

April 13, 2026 — Johnson & Johnson has announced favorable 12-month interim effectiveness and safety results from ...

Home April 13, 2026
Home
News

In a milestone for Broward Health in Ft. Lauderdale, Fla., Jose L. Baez-Escudero, M.D., chief of cardiology and ...

Home March 24, 2026
Home
News

Feb. 6, 2026 — Abbott has announced new clinical data from two late-breaking presentations at AF Symposium in Boston ...

Home February 06, 2026
Home
Subscribe Now